NL7013068A
(es)
|
1969-09-17 |
1971-03-19 |
|
|
US4537889A
(en)
|
1982-12-27 |
1985-08-27 |
Eli Lilly And Company |
Inotropic agents
|
US4625040A
(en)
|
1984-09-24 |
1986-11-25 |
Pennwalt Corporation |
N-(phenyl) or N-(phenylcyclopropyl)-2,5-dihydro-2-oxo-4[(substituted phenyl)amino]-3-furancarboxamide derivatives
|
US4614810A
(en)
|
1984-09-24 |
1986-09-30 |
Pennwalt Corporation |
4,5-dihydro-4-oxo-2-[(2-trans-phenylcyclopropyl)amino]-3-furancarboxylic acids and derivatives thereof
|
FR2607813B1
(fr)
|
1986-12-05 |
1989-03-31 |
Montpellier I Universite |
Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique
|
JPH032778Y2
(es)
|
1986-12-15 |
1991-01-24 |
|
|
AU622330B2
(en)
|
1989-06-23 |
1992-04-02 |
Takeda Chemical Industries Ltd. |
Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
|
JP2844351B2
(ja)
|
1989-07-13 |
1999-01-06 |
株式会社科薬 |
安定なポリミキシン系抗生物質水性溶液
|
IL96432A0
(en)
|
1989-11-30 |
1991-08-16 |
Schering Ag |
Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives
|
FR2662163A1
(fr)
|
1990-05-16 |
1991-11-22 |
Lipha |
Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant.
|
EP0649425B1
(en)
|
1992-06-17 |
1999-03-10 |
PHARMACIA & UPJOHN COMPANY |
Pyridino-, pyrrolidino- and azepino-substituted oximes useful as anti-atherosclerosis and anti-hypercholesterolemic agents
|
JP2923139B2
(ja)
|
1992-10-05 |
1999-07-26 |
三井化学株式会社 |
製 剤
|
DE4327027A1
(de)
|
1993-02-15 |
1994-08-18 |
Bayer Ag |
Imidazoazine
|
FR2711993B1
(fr)
|
1993-11-05 |
1995-12-01 |
Rhone Poulenc Rorer Sa |
Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation.
|
US5932223A
(en)
|
1996-09-26 |
1999-08-03 |
Merck & Co., Inc. |
Rotavirus vaccine formulations
|
EP1050535A4
(en)
|
1997-11-11 |
2001-04-25 |
Ono Pharmaceutical Co |
CONDENSED PYRAZINE DERIVATIVES
|
JP2000319277A
(ja)
|
1999-05-11 |
2000-11-21 |
Ono Pharmaceut Co Ltd |
縮合ピラジン化合物およびその化合物を有効成分とする薬剤
|
JP2000319278A
(ja)
|
1999-05-11 |
2000-11-21 |
Ono Pharmaceut Co Ltd |
縮合ピラジン化合物およびその化合物を有効成分とする薬剤
|
JP4032566B2
(ja)
|
1999-06-21 |
2008-01-16 |
東レ株式会社 |
発光素子
|
JP4041624B2
(ja)
|
1999-07-21 |
2008-01-30 |
三井化学株式会社 |
有機電界発光素子
|
JP2001057292A
(ja)
|
1999-08-20 |
2001-02-27 |
Toray Ind Inc |
発光素子
|
NZ518052A
(en)
|
1999-09-28 |
2005-04-29 |
Panacea Biotec Ltd |
Controlled release compositions comprising nimesulide (4-nitro-2-phenoxymethanesulfonanilide) for a once-a-day oral dosage to treat diseases such as arthritis
|
SE9903611D0
(sv)
|
1999-10-06 |
1999-10-06 |
Astra Ab |
Novel compounds III
|
DE19948434A1
(de)
|
1999-10-08 |
2001-06-07 |
Gruenenthal Gmbh |
Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
|
JP4409680B2
(ja)
|
1999-10-18 |
2010-02-03 |
株式会社ヤクルト本社 |
三環性縮合イミダゾール誘導体
|
KR100830859B1
(ko)
|
2000-04-27 |
2008-05-21 |
아스텔라스세이야쿠 가부시키가이샤 |
이미다조피리딘 유도체 및 이를 함유하는 의약 조성물
|
US6403588B1
(en)
|
2000-04-27 |
2002-06-11 |
Yamanouchi Pharmaceutical Co., Ltd. |
Imidazopyridine derivatives
|
CA2413330A1
(en)
|
2000-06-28 |
2002-01-03 |
Smithkline Beecham P.L.C. |
Wet milling process
|
AR029538A1
(es)
|
2000-07-06 |
2003-07-02 |
Wyeth Corp |
Composiciones farmaceuticas de agentes estrogenicos
|
CA2419626A1
(en)
|
2000-07-14 |
2002-01-24 |
Rajagopal Bakthavatachalam |
Imidazo¬1,2-a|pyrazines for the treatment of neurological disorders
|
DE10050663A1
(de)
|
2000-10-13 |
2002-04-18 |
Gruenenthal Gmbh |
Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
|
AU2001295992A1
(en)
|
2000-10-24 |
2002-05-06 |
Sankyo Company Limited |
Imidazopyridine derivatives
|
JP2002205992A
(ja)
|
2000-11-08 |
2002-07-23 |
Takeda Chem Ind Ltd |
二環式トリアゾロン誘導体およびそれを含有する除草剤
|
AU2002212530B2
(en)
|
2000-11-10 |
2006-08-17 |
Merck Sharp & Dohme Limited |
Imidazo-triazine derivatives as ligands for GABA receptors
|
US20040058938A1
(en)
|
2000-12-13 |
2004-03-25 |
Oliver Cullmann |
Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds
|
EP1217000A1
(en)
|
2000-12-23 |
2002-06-26 |
Aventis Pharma Deutschland GmbH |
Inhibitors of factor Xa and factor VIIa
|
TWI312347B
(en)
|
2001-02-08 |
2009-07-21 |
Eisai R&D Man Co Ltd |
Bicyclic nitrogen-containing condensed ring compounds
|
EP1377549A1
(en)
|
2001-03-12 |
2004-01-07 |
Millennium Pharmaceuticals, Inc. |
Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
|
AR035543A1
(es)
|
2001-06-26 |
2004-06-16 |
Japan Tobacco Inc |
Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
|
IL159811A0
(en)
|
2001-07-13 |
2004-06-20 |
Neurogen Corp |
Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
|
US6921762B2
(en)
|
2001-11-16 |
2005-07-26 |
Amgen Inc. |
Substituted indolizine-like compounds and methods of use
|
JP2005519915A
(ja)
|
2002-01-18 |
2005-07-07 |
セレテック・リミテッド・ライアビリティ・カンパニー |
Edg受容体に関連する症状の処置方法
|
US20050113283A1
(en)
|
2002-01-18 |
2005-05-26 |
David Solow-Cordero |
Methods of treating conditions associated with an EDG-4 receptor
|
WO2004017950A2
(en)
|
2002-08-22 |
2004-03-04 |
Piramed Limited |
Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
|
UA80296C2
(en)
|
2002-09-06 |
2007-09-10 |
Biogen Inc |
Imidazolopyridines and methods of making and using the same
|
CA2502148A1
(en)
|
2002-10-16 |
2005-02-17 |
Board Of Regents, The University Of Texas System |
Methods and compositions for increasing the efficacy of biologically-active ingredients
|
JP2006514043A
(ja)
|
2002-12-20 |
2006-04-27 |
ファルマシア・コーポレーション |
マイトジェン活性化タンパク質キナーゼ−活性化タンパク質キナーゼ−2を阻害する化合物
|
US7189723B2
(en)
|
2003-02-10 |
2007-03-13 |
Cgi Pharmaceuticals, Inc. |
Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
|
US7186832B2
(en)
|
2003-02-20 |
2007-03-06 |
Sugen Inc. |
Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
|
GB0303910D0
(en)
|
2003-02-20 |
2003-03-26 |
Merck Sharp & Dohme |
Therapeutic agents
|
US7157460B2
(en)
|
2003-02-20 |
2007-01-02 |
Sugen Inc. |
Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
|
AU2004220225B2
(en)
|
2003-03-14 |
2010-06-17 |
Ono Pharmaceutical Co., Ltd. |
Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
|
WO2004089416A2
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
|
WO2004089380A2
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Pharmaceutical use of fused 1,2,4-triazoles
|
US7579355B2
(en)
|
2003-04-24 |
2009-08-25 |
Merck & Co., Inc. |
Inhibitors of Akt activity
|
SE0301653D0
(sv)
|
2003-06-05 |
2003-06-05 |
Astrazeneca Ab |
Novel compounds
|
JP4920410B2
(ja)
|
2003-07-14 |
2012-04-18 |
アリーナ ファーマシューティカルズ, インコーポレイテッド |
代謝モジュレーターとしての縮合アリールおよびヘテロアリール誘導体ならびに代謝に関連する障害の予防および治療
|
US7538120B2
(en)
|
2003-09-03 |
2009-05-26 |
Array Biopharma Inc. |
Method of treating inflammatory diseases
|
ATE551997T1
(de)
|
2003-09-12 |
2012-04-15 |
Merck Serono Sa |
Sulfonamid-derivate zur behandlung von diabetes
|
JP2005089352A
(ja)
|
2003-09-16 |
2005-04-07 |
Kissei Pharmaceut Co Ltd |
新規なイミダゾ[1,5−a]ピラジン誘導体、それを含有する医薬組成物およびそれらの用途
|
ATE369370T1
(de)
|
2003-10-10 |
2007-08-15 |
Pfizer Prod Inc |
Substituierte 2h-(1,2,4)triazolo(4,3-a)pyrazine als gsk-3-inhibitoren
|
US7419978B2
(en)
|
2003-10-22 |
2008-09-02 |
Bristol-Myers Squibb Company |
Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
|
WO2005044793A2
(en)
|
2003-10-31 |
2005-05-19 |
Takeda Pharmaceutical Company Limited |
Nitrogen-containing fused heterocyclic compounds
|
WO2005063241A1
(ja)
|
2003-12-26 |
2005-07-14 |
Ono Pharmaceutical Co., Ltd. |
ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および/または治療剤
|
WO2005077948A1
(ja)
|
2004-02-16 |
2005-08-25 |
Daiichi Pharmaceutical Co., Ltd. |
抗真菌作用複素環化合物
|
US7306631B2
(en)
|
2004-03-30 |
2007-12-11 |
The Procter & Gamble Company |
Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
|
MXPA06012449A
(es)
*
|
2004-04-26 |
2007-01-17 |
Pfizer |
Inhibidores de la enzima integrasa de vih.
|
EP2258349B1
(en)
|
2004-05-11 |
2014-07-16 |
Egalet Ltd. |
Swellable dosage form comprising gellan gum
|
TW200612918A
(en)
|
2004-07-29 |
2006-05-01 |
Threshold Pharmaceuticals Inc |
Lonidamine analogs
|
WO2006018727A2
(en)
|
2004-08-18 |
2006-02-23 |
Pharmacia & Upjohn Company Llc |
Triazolopyridine compounds useful for the treatment of inflammation
|
EP1799671A4
(en)
|
2004-09-02 |
2009-06-10 |
Smithkline Beecham Corp |
CHEMICAL COMPOUNDS
|
JP2008515874A
(ja)
|
2004-10-07 |
2008-05-15 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
抗菌薬
|
KR20070086595A
(ko)
|
2004-11-22 |
2007-08-27 |
쓰레솔드 파마슈티컬스, 인코포레이티드 |
튜불린 결합 항암제 및 이의 전구약물
|
JP2008521858A
(ja)
|
2004-12-01 |
2008-06-26 |
ラボラトワール セローノ ソシエテ アノニム |
過増殖性疾患を処置するための[1,2,4]トリアゾロ[4,3−a]ピリジン誘導体
|
US20070293456A9
(en)
|
2004-12-30 |
2007-12-20 |
Anthony Hayford |
Method for the synthesis of 3-substituted indolizine and benzoindolizine compounds
|
US7456289B2
(en)
|
2004-12-31 |
2008-11-25 |
National Health Research Institutes |
Anti-tumor compounds
|
CA2598536C
(en)
|
2005-02-22 |
2011-04-05 |
Pfizer Inc. |
Oxyindole derivatives as 5ht4 receptor agonists
|
ITBO20050123A1
(it)
|
2005-03-07 |
2005-06-06 |
Alfa Wassermann Spa |
Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
|
TW200716594A
(en)
|
2005-04-18 |
2007-05-01 |
Neurogen Corp |
Substituted heteroaryl CB1 antagonists
|
CA2611391A1
(en)
|
2005-06-09 |
2006-12-14 |
Oncalis Ag |
Angiogenesis inhibitors
|
US7579360B2
(en)
|
2005-06-09 |
2009-08-25 |
Bristol-Myers Squibb Company |
Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
US7572807B2
(en)
|
2005-06-09 |
2009-08-11 |
Bristol-Myers Squibb Company |
Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
|
US7452892B2
(en)
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
US7632837B2
(en)
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
TW200726765A
(en)
|
2005-06-17 |
2007-07-16 |
Bristol Myers Squibb Co |
Triazolopyridine cannabinoid receptor 1 antagonists
|
EP1928237A4
(en)
|
2005-09-02 |
2011-03-09 |
Abbott Lab |
NEW HETEROCYCLES BASED ON IMIDAZO
|
CA2621983A1
(en)
|
2005-09-09 |
2007-03-22 |
Schering Corporation |
Azafused cyclin dependent kinase inhibitors
|
RU2008122967A
(ru)
|
2005-11-10 |
2009-12-20 |
Шеринг Корпорейшн (US) |
Имидазопиразины в качестве ингибиторов протеинкиназ
|
EP1959966B1
(en)
|
2005-11-28 |
2020-06-03 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone formulations and methods for the making and use thereof
|
EP1968977B1
(en)
|
2005-12-27 |
2011-12-14 |
F. Hoffmann-La Roche AG |
Aryl-isoxazol-4-yl-imidazo[1,5-a]pyridine derivatives
|
WO2007074491A1
(en)
|
2005-12-28 |
2007-07-05 |
Universita Degli Studi Di Siena |
HETEROTRICYCLIC AMIDE DERIVATIVES AS NEUROKININ-l (NKl) RECEPTOR LIGANDS
|
PE20070978A1
(es)
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
BRPI0710110A2
(pt)
|
2006-03-31 |
2011-08-02 |
Novartis Ag |
compostos orgánicos
|
MX2008015747A
(es)
|
2006-06-06 |
2008-12-19 |
Schering Corp |
Imidazopirazinas como inhibidores de la proteina quinasa.
|
US20090175852A1
(en)
|
2006-06-06 |
2009-07-09 |
Schering Corporation |
Imidazopyrazines as protein kinase inhibitors
|
US9216963B2
(en)
|
2006-06-22 |
2015-12-22 |
Medibeacon Inc. |
Pyrazine derivatives with extended conjugation and methods of using the same in optical applications
|
EP2029554B1
(en)
|
2006-06-22 |
2014-03-19 |
MediBeacon, LLC |
Pyrazine derivatives and uses thereof in renal monitoring
|
EP2032560B1
(en)
|
2006-06-29 |
2013-05-01 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic and tricyclic thrombin receptor antagonists
|
WO2008005423A1
(en)
|
2006-07-03 |
2008-01-10 |
Cambrex Charles City, Inc. |
Improved method of making sufentanil
|
US7501438B2
(en)
|
2006-07-07 |
2009-03-10 |
Forest Laboratories Holdings Limited |
Pyridoimidazole derivatives
|
PE20080403A1
(es)
|
2006-07-14 |
2008-04-25 |
Amgen Inc |
Derivados heterociclicos fusionados y metodos de uso
|
US8198448B2
(en)
|
2006-07-14 |
2012-06-12 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
US20080021026A1
(en)
|
2006-07-20 |
2008-01-24 |
Mehmet Kahraman |
Benzothiophene inhibitors of rho kinase
|
WO2008027812A2
(en)
|
2006-08-28 |
2008-03-06 |
Forest Laboratories Holdings Limited |
Imidazopyridine and imidazopyrimidine derivatives
|
DE102006041292A1
(de)
|
2006-09-01 |
2008-03-06 |
Henkel Kgaa |
Wasserstoffperoxid-Aktivierung mit N-Heterocyclen
|
WO2008037607A1
(de)
|
2006-09-25 |
2008-04-03 |
Basf Se |
Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen
|
ATE542818T1
(de)
|
2006-10-11 |
2012-02-15 |
Amgen Inc |
Imidazo- und triazolopyridinverbindungen und verfahren zu deren anwendung
|
CA2669094A1
(en)
|
2006-11-08 |
2008-05-29 |
Novavax,Inc. |
Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
|
WO2008056176A1
(en)
|
2006-11-10 |
2008-05-15 |
Scottish Biomedical Limited |
Pyrazolopyrimidines as phosphodiesterase inhibitors
|
SI3034075T1
(sl)
|
2006-11-22 |
2018-12-31 |
Incyte Holdings Corporation |
Imidazotriazini in imidazopirimidini kot inhibitorji kinaze
|
US7977352B2
(en)
|
2006-12-01 |
2011-07-12 |
Galapagos Nv |
Triazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases
|
AU2007338631A1
(en)
|
2006-12-22 |
2008-07-03 |
Combinatorx, Incorporated |
Pharmaceutical compositions for treatment of parkinson's disease and related disorders
|
JP5612860B2
(ja)
|
2007-03-09 |
2014-10-22 |
プロビオドルグ エージー |
グルタミニルシクラーゼ阻害剤としてのイミダゾ[1,5−a]ピリジン誘導体
|
DE102007012645A1
(de)
|
2007-03-16 |
2008-09-18 |
Bayer Healthcare Ag |
Substituierte Imidazo- und Triazolopyrimidine
|
EP1972628A1
(en)
|
2007-03-21 |
2008-09-24 |
Schwarz Pharma Ag |
Indolizines and aza-analog derivatives thereof as CNS active compounds
|
CN101679428A
(zh)
|
2007-04-16 |
2010-03-24 |
利奥制药有限公司 |
用于治疗皮肤疾病的作为磷酸二酯酶抑制剂的三唑并吡啶类
|
JP2010524953A
(ja)
|
2007-04-17 |
2010-07-22 |
ブリストル−マイヤーズ スクイブ カンパニー |
縮合ヘテロ環11−β−ヒドロキシステロイドデヒドロゲナーゼI型阻害剤
|
WO2008141239A1
(en)
|
2007-05-10 |
2008-11-20 |
Acadia Pharmaceuticals Inc. |
Imidazol [1,2-a] pyridines and related compounds with activity at cannabinoid cb2 receptors
|
CA2687558C
(en)
|
2007-05-21 |
2015-07-14 |
Toray Industries, Inc. |
Oral preparation comprising specific organic acid, and method for improvement in elution property and chemical stability of oral preparation
|
SG182187A1
(en)
|
2007-06-08 |
2012-07-30 |
Abbott Gmbh & Co Kg |
5-heteroaryl substituted indazoles as kinase inhibitors
|
US8648069B2
(en)
|
2007-06-08 |
2014-02-11 |
Abbvie Inc. |
5-substituted indazoles as kinase inhibitors
|
PE20090365A1
(es)
|
2007-06-14 |
2009-04-04 |
Schering Corp |
Imidazopirazinas como inhibidores de proteina quinasa
|
CL2008001839A1
(es)
|
2007-06-21 |
2009-01-16 |
Incyte Holdings Corp |
Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
|
US20090004281A1
(en)
|
2007-06-26 |
2009-01-01 |
Biovail Laboratories International S.R.L. |
Multiparticulate osmotic delivery system
|
CA2693232A1
(en)
|
2007-07-18 |
2009-01-22 |
Novartis Ag |
Bicyclic heteroaryl compounds and their use as kinase inhibitors
|
WO2009017701A2
(en)
|
2007-07-31 |
2009-02-05 |
Schering Corporation |
Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment
|
WO2009017954A1
(en)
|
2007-08-01 |
2009-02-05 |
Phenomix Corporation |
Inhibitors of jak2 kinase
|
CN101842098A
(zh)
|
2007-08-10 |
2010-09-22 |
基因实验室技术有限公司 |
用于治疗病毒感染的含氮的二环化学实体
|
US20090047336A1
(en)
|
2007-08-17 |
2009-02-19 |
Hong Kong Baptist University |
novel formulation of dehydrated lipid vesicles for controlled release of active pharmaceutical ingredient via inhalation
|
FR2920090A1
(fr)
|
2007-08-24 |
2009-02-27 |
Oreal |
Composition tinctoriale comprenant une base d'oxydation aminopyrazolopyridine particuliere, un coupleur et un tensioactif particulier.
|
FR2920091A1
(fr)
|
2007-08-24 |
2009-02-27 |
Oreal |
Composition tinctoriale comprenant une base d'oxydation aminopyrazolopyridine, un coupleur et un polyol particulier.
|
KR20090022616A
(ko)
|
2007-08-31 |
2009-03-04 |
한올제약주식회사 |
베실산클로피도그렐 함유 경구투여용 약제
|
US8119658B2
(en)
|
2007-10-01 |
2012-02-21 |
Bristol-Myers Squibb Company |
Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
GB0719803D0
(en)
|
2007-10-10 |
2007-11-21 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
TWI453021B
(zh)
|
2007-10-11 |
2014-09-21 |
Astrazeneca Ab |
新穎蛋白質激酶b抑制劑
|
CN101820916A
(zh)
|
2007-10-12 |
2010-09-01 |
诺瓦提斯公司 |
包含鞘氨醇1磷酸(s1p)受体调节剂的组合物
|
JP5710268B2
(ja)
|
2007-12-19 |
2015-04-30 |
ジェネンテック, インコーポレイテッド |
8−アニリノイミダゾピリジン及びその抗ガン及び/又は抗炎症剤としての使用
|
PE20091268A1
(es)
|
2007-12-19 |
2009-09-19 |
Amgen Inc |
Derivados heterociclicos como inhibidores de pi3 quinasa
|
KR100988233B1
(ko)
|
2007-12-26 |
2010-10-18 |
한미홀딩스 주식회사 |
클로피도그렐 1,5-나프탈렌 다이술폰산 염 또는 이의수화물의 약학 조성물 및 제제
|
UA101493C2
(ru)
|
2008-03-11 |
2013-04-10 |
Инсайт Корпорейшн |
Производные азетидина и циклобутана как ингибиторы jak
|
US8507501B2
(en)
|
2008-03-13 |
2013-08-13 |
The Brigham And Women's Hospital, Inc. |
Inhibitors of the BMP signaling pathway
|
US8637542B2
(en)
|
2008-03-14 |
2014-01-28 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
EP2444403A1
(en)
|
2008-04-18 |
2012-04-25 |
Shionogi Co., Ltd. |
Heterocyclic compound having inhibitory activity on PI3K
|
DE102008023801A1
(de)
|
2008-05-15 |
2009-11-19 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
|
US8349210B2
(en)
|
2008-06-27 |
2013-01-08 |
Transitions Optical, Inc. |
Mesogenic stabilizers
|
WO2010010184A1
(en)
|
2008-07-25 |
2010-01-28 |
Galapagos Nv |
[1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
|
WO2010010189A1
(en)
|
2008-07-25 |
2010-01-28 |
Galapagos Nv |
Novel compounds useful for the treatment of degenerative and inflammatory diseases
|
WO2010010188A1
(en)
|
2008-07-25 |
2010-01-28 |
Galapagos Nv |
Novel compounds useful for the treatment of degenerative and inflammatory diseases.
|
WO2010010187A1
(en)
|
2008-07-25 |
2010-01-28 |
Galapagos Nv |
Novel compounds useful for the treatment of degenerative and inflammatory diseases
|
UY32049A
(es)
|
2008-08-14 |
2010-03-26 |
Takeda Pharmaceutical |
Inhibidores de cmet
|
TR200806298A2
(tr)
|
2008-08-22 |
2010-03-22 |
Bi̇lgi̇ç Mahmut |
Farmasötik formülasyon
|
WO2010033906A2
(en)
|
2008-09-19 |
2010-03-25 |
President And Fellows Of Harvard College |
Efficient induction of pluripotent stem cells using small molecule compounds
|
JP2010070503A
(ja)
|
2008-09-19 |
2010-04-02 |
Daiichi Sankyo Co Ltd |
抗真菌作用2−アミノトリアゾロピリジン誘導体
|
US8703778B2
(en)
|
2008-09-26 |
2014-04-22 |
Intellikine Llc |
Heterocyclic kinase inhibitors
|
WO2010043721A1
(en)
|
2008-10-17 |
2010-04-22 |
Oryzon Genomics, S.A. |
Oxidase inhibitors and their use
|
WO2010048149A2
(en)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
DK2376490T3
(da)
|
2008-12-04 |
2013-04-15 |
Proximagen Ltd |
Imidazopyridinforbindelser
|
US8450321B2
(en)
|
2008-12-08 |
2013-05-28 |
Gilead Connecticut, Inc. |
6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
|
WO2010084160A1
(en)
|
2009-01-21 |
2010-07-29 |
Oryzon Genomics S.A. |
Phenylcyclopropylamine derivatives and their medical use
|
EP2393813B1
(en)
|
2009-02-04 |
2013-07-31 |
Vitae Pharmaceuticals, Inc. |
Cyclic inhibitors of 11 ß-hydroxysteroid dehydrogenase 1 useful for the treatment of diseases related to elevated level of cortisol
|
US20100209489A1
(en)
|
2009-02-04 |
2010-08-19 |
Supernus Pharmaceuticals, Inc. |
Formulations of desvenlafaxine
|
TR200900878A2
(tr)
|
2009-02-05 |
2010-08-23 |
Bi̇lgi̇ç Mahmut |
Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar
|
TR200900879A2
(tr)
|
2009-02-05 |
2010-08-23 |
Bi̇lgi̇ç Mahmut |
Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler
|
EP2396331B1
(en)
|
2009-02-13 |
2013-10-16 |
Bayer Intellectual Property GmbH |
Fused pyrimidines as akt inhibitors
|
KR20100101054A
(ko)
|
2009-03-07 |
2010-09-16 |
주식회사 메디젠텍 |
세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
|
WO2010107404A1
(en)
|
2009-03-16 |
2010-09-23 |
Mahmut Bilgic |
Stable pharmaceutical combinations
|
AR076052A1
(es)
|
2009-03-20 |
2011-05-18 |
Incyte Corp |
Derivados de pirimidinas sustituidas, composiciones farmaceuticas que los contienen y uso de los mismos en trastornos asociados con receptores de histamina h4, tales como trastornos inflamatorios, prurito y dolor.
|
AU2010231615B2
(en)
|
2009-03-31 |
2014-05-15 |
Kissei Pharmaceutical Co., Ltd. |
Indolizine derivative and use thereof for medical purposes
|
ES2475091T3
(es)
|
2009-04-16 |
2014-07-10 |
Centro Nacional De Investigaciones Oncol�Gicas (Cnio) |
Imidazopirazinas como inhibidores de proteína cinasas
|
TWI461426B
(zh)
|
2009-05-27 |
2014-11-21 |
Merck Sharp & Dohme |
(二氫)咪唑並異〔5,1-a〕喹啉類
|
EP2440563A1
(en)
|
2009-06-10 |
2012-04-18 |
Sunovion Pharmaceuticals Inc. |
Histamine h3 inverse agonists and antagonists and methods of use thereof
|
US8686009B2
(en)
|
2009-06-25 |
2014-04-01 |
Alkermes Pharma Ireland Limited |
Prodrugs of NH-acidic compounds
|
EA026693B1
(ru)
|
2009-08-17 |
2017-05-31 |
Интелликайн ЭлЭлСи |
Производные бензоксазола и бензотиазола в качестве ингибиторов pi3-киназы
|
US9708255B2
(en)
|
2009-08-18 |
2017-07-18 |
Robert A. Casero |
(bis)urea and (bis)thiourea compounds as epigenic modulators of lysine-specific demethylase 1 and methods of treating disorders
|
EP2473495A1
(en)
|
2009-09-18 |
2012-07-11 |
Almac Discovery Limited |
Pharmaceutical compounds
|
RU2602814C2
(ru)
|
2009-09-25 |
2016-11-20 |
Оризон Дженомикс С.А. |
Лизинспецифические ингибиторы деметилазы-1 и их применение
|
WO2011042217A1
(en)
|
2009-10-09 |
2011-04-14 |
Oryzon Genomics S.A. |
Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
|
WO2011050245A1
(en)
|
2009-10-23 |
2011-04-28 |
Yangbo Feng |
Bicyclic heteroaryls as kinase inhibitors
|
US8541404B2
(en)
|
2009-11-09 |
2013-09-24 |
Elexopharm Gmbh |
Inhibitors of the human aldosterone synthase CYP11B2
|
US8614315B2
(en)
|
2009-12-25 |
2013-12-24 |
Mahmut Bilgic |
Cefdinir and cefixime formulations and uses thereof
|
CA2787714C
(en)
|
2010-01-22 |
2019-04-09 |
Joaquin Pastor Fernandez |
Inhibitors of pi3 kinase
|
WO2011097607A1
(en)
|
2010-02-08 |
2011-08-11 |
Southern Research Institute |
Anti-viral treatment and assay to screen for anti-viral agent
|
US9616058B2
(en)
|
2010-02-24 |
2017-04-11 |
Oryzon Genomics, S.A. |
Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
|
WO2011106573A2
(en)
|
2010-02-24 |
2011-09-01 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
|
TW201200518A
(en)
|
2010-03-10 |
2012-01-01 |
Kalypsys Inc |
Heterocyclic inhibitors of histamine receptors for the treatment of disease
|
ES2572387T3
(es)
|
2010-03-18 |
2016-05-31 |
Pasteur Institut Korea |
Compuestos anti-infecciosos
|
US9468642B2
(en)
|
2010-03-18 |
2016-10-18 |
Bayer Intellectual Property Gmbh |
Imidazopyrazines
|
EP2552920B1
(en)
|
2010-04-02 |
2017-03-15 |
Ogeda Sa |
Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders
|
ES2607081T3
(es)
|
2010-04-19 |
2017-03-29 |
Oryzon Genomics, S.A. |
Inhibidores de desmetilasa específica de lisina-1 y su uso
|
EP2560949B1
(en)
|
2010-04-20 |
2015-12-02 |
Università degli Studi di Roma "La Sapienza" |
Tranylcypromine derivatives as inhibitors of histone demethylase lsd1 and/or lsd2
|
RU2012136643A
(ru)
|
2010-04-28 |
2014-06-10 |
Дайити Санкио Компани, Лимитед |
[5,6]- гетероциклическое соединение
|
WO2011141713A1
(en)
|
2010-05-13 |
2011-11-17 |
Centro Nacional De Investigaciones Oncologicas (Cnio) |
New bicyclic compounds as pi3-k and mtor inhibitors
|
WO2011143365A1
(en)
|
2010-05-13 |
2011-11-17 |
Amgen Inc. |
Nitrogen heterocyclic compounds useful as pde10 inhibitors
|
CN102247321A
(zh)
|
2010-05-20 |
2011-11-23 |
上海亚盛医药科技有限公司 |
一种阿朴棉子酚酮自乳化药物传递系统及其制备方法
|
EP2575808A1
(en)
|
2010-05-28 |
2013-04-10 |
Mahmut Bilgic |
Combination of antihypertensive agents
|
CN102295642B
(zh)
|
2010-06-25 |
2016-04-06 |
中国人民解放军军事医学科学院毒物药物研究所 |
2-芳基咪唑并[1,2-a]吡啶-3-乙酰胺衍生物、其制备方法及用途
|
CN103096977B
(zh)
|
2010-07-02 |
2017-02-15 |
吉利德科学公司 |
作为离子通道调节剂的稠杂环化合物
|
ES2552841T3
(es)
|
2010-07-12 |
2015-12-02 |
Bayer Intellectual Property Gmbh |
Imidazo[1,2-a]pirimidinas y -piridinas sustituidas
|
WO2012009475A1
(en)
|
2010-07-14 |
2012-01-19 |
Oregon Health & Science University |
Methods of treating cancer with inhibition of lysine-specific demethylase 1
|
CN101987082B
(zh)
|
2010-07-16 |
2013-04-03 |
钟术光 |
固体制剂及其制备方法
|
CN101987081B
(zh)
|
2010-07-16 |
2012-08-08 |
钟术光 |
一种控释制剂
|
RU2611437C2
(ru)
|
2010-07-29 |
2017-02-22 |
Оризон Дженомикс С.А. |
Ингибиторы деметилазы lsd1 на основе арилциклопропиламина и их применение в медицине
|
WO2012016133A2
(en)
|
2010-07-29 |
2012-02-02 |
President And Fellows Of Harvard College |
Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
|
WO2012013727A1
(en)
|
2010-07-29 |
2012-02-02 |
Oryzon Genomics S.A. |
Cyclopropylamine derivatives useful as lsd1 inhibitors
|
WO2012034116A2
(en)
|
2010-09-10 |
2012-03-15 |
The Johns Hopkins University |
Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
|
CN102397552B
(zh)
|
2010-09-10 |
2016-06-08 |
广州自远生物科技有限公司 |
一种含喹诺酮类的药物复合制剂及其制备方法和应用
|
US9643969B2
(en)
|
2010-09-29 |
2017-05-09 |
Kissei Pharmaceutical Co., Ltd. |
(aza)indolizine derivative and pharmaceutical use thereof
|
US20130303545A1
(en)
|
2010-09-30 |
2013-11-14 |
Tamara Maes |
Cyclopropylamine derivatives useful as lsd1 inhibitors
|
US20120108500A1
(en)
|
2010-10-07 |
2012-05-03 |
Naoki Sakane |
Compositions and Methods for Modulating Immunodeficiency Virus Transcription
|
MX343596B
(es)
|
2010-10-18 |
2016-11-11 |
E I Du Pont De Nemours And Company * |
Sulfonamidas nematocidas.
|
WO2012052745A1
(en)
|
2010-10-21 |
2012-04-26 |
Centro Nacional De Investigaciones Oncológicas (Cnio) |
Combinations of pi3k inhibitors with a second anti -tumor agent
|
SI2630146T1
(sl)
|
2010-10-21 |
2020-12-31 |
Medivation Technologies Llc |
Kristalinična tosilatna sol (8S,9R)-5-fluoro-8-(4-fluorofenil)-9-(1-metil-1H-1,2,4-triazol-5-IL)- 8,9-dihidro-2H-pirido(4,3,2-DE)ftalazin-3(7H)-ON
|
EP2444084A1
(en)
|
2010-10-21 |
2012-04-25 |
Centro Nacional de Investigaciones Oncológicas (CNIO) |
Use of PI3K inibitors for the treatment of obesity
|
WO2012071469A2
(en)
|
2010-11-23 |
2012-05-31 |
Nevada Cancer Institute |
Histone demethylase inhibitors and uses thereof for treatment o f cancer
|
WO2012072713A2
(en)
|
2010-11-30 |
2012-06-07 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
|
US20140031547A1
(en)
|
2010-12-14 |
2014-01-30 |
Electrophoretics Limited |
CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
|
US20140187548A1
(en)
|
2010-12-17 |
2014-07-03 |
Bayer Intellectual Property Gmbh |
6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
|
EP2651946B1
(en)
|
2010-12-17 |
2015-05-27 |
Bayer Intellectual Property GmbH |
2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
|
CA2821817A1
(en)
|
2010-12-17 |
2012-06-21 |
Bayer Intellectual Property Gmbh |
Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
|
US20140135319A1
(en)
|
2010-12-17 |
2014-05-15 |
Bayer Intellectual Property Gmbh |
6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
|
UY33805A
(es)
|
2010-12-17 |
2012-07-31 |
Boehringer Ingelheim Int |
?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?.
|
EP2655334B1
(en)
|
2010-12-22 |
2018-10-03 |
Eutropics Pharmaceuticals, Inc. |
Compositions and methods useful for treating diseases
|
TWI617559B
(zh)
|
2010-12-22 |
2018-03-11 |
江蘇恆瑞醫藥股份有限公司 |
2-芳基咪唑并[1,2-b]嗒.2-苯基咪唑并[1,2-a]吡啶,和2-苯基咪唑并[1,2-a]吡衍生物
|
JP2014504604A
(ja)
|
2011-01-21 |
2014-02-24 |
ザ ジェネラル ホスピタル コーポレイション |
心血管疾患のための組成物および方法
|
US20140163041A1
(en)
|
2011-02-08 |
2014-06-12 |
Oryzon Genomics S.A. |
Lysine demethylase inhibitors for myeloproliferative or lymphoproliferative diseases or disorders
|
EP2712315B1
(en)
|
2011-02-08 |
2021-11-24 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for myeloproliferative disorders
|
WO2012116237A2
(en)
|
2011-02-23 |
2012-08-30 |
Intellikine, Llc |
Heterocyclic compounds and uses thereof
|
US9464065B2
(en)
|
2011-03-24 |
2016-10-11 |
The Scripps Research Institute |
Compounds and methods for inducing chondrogenesis
|
CA2831143C
(en)
|
2011-03-25 |
2019-05-21 |
Glaxosmithkline Intellectual Property Development Limited |
Cyclopropylamines as lsd1 inhibitors
|
WO2012147890A1
(ja)
|
2011-04-27 |
2012-11-01 |
持田製薬株式会社 |
新規アゾール誘導体
|
US20140296255A1
(en)
|
2011-05-19 |
2014-10-02 |
Oryzong Genomics, S.A. |
Lysine demethylase inhibitors for thrombosis and cardiovascular diseases
|
EP2524918A1
(en)
|
2011-05-19 |
2012-11-21 |
Centro Nacional de Investigaciones Oncológicas (CNIO) |
Imidazopyrazines derivates as kinase inhibitors
|
WO2012156531A2
(en)
|
2011-05-19 |
2012-11-22 |
Oryzon Genomics, S.A. |
Lysine demethylase inhibitors for inflammatory diseases or conditions
|
RU2013156437A
(ru)
|
2011-06-07 |
2015-07-20 |
СПАЙ Груп Лтд. |
Композиция и способы улучшения стабильности и продления срока хранения чувствительных пищевых добавок и пищевых продуктов из них
|
US8691807B2
(en)
|
2011-06-20 |
2014-04-08 |
Incyte Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
|
TW201311149A
(zh)
|
2011-06-24 |
2013-03-16 |
Ishihara Sangyo Kaisha |
有害生物防治劑
|
EP2548877A1
(en)
|
2011-07-19 |
2013-01-23 |
MSD Oss B.V. |
4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
|
UA114406C2
(uk)
*
|
2011-08-09 |
2017-06-12 |
Такеда Фармасьютікал Компані Лімітед |
Похідні циклопропанаміну як інгібітори lsd1
|
LT2744330T
(lt)
|
2011-08-15 |
2020-10-26 |
University Of Utah Research Foundation |
Pakeisti (e)-n`-(1-feniletilideno) benzohidrazido analogai, kaip histonų demetilazės inhibitoriai
|
WO2013033688A1
(en)
|
2011-09-01 |
2013-03-07 |
The Brigham And Women's Hospital, Inc. |
Treatment of cancer
|
JP6067019B2
(ja)
|
2011-09-02 |
2017-01-25 |
プロメガ コーポレイションPromega Corporation |
代謝的に活性な細胞の酸化還元状態を評価するための化合物及び方法、ならびにnad(p)/nad(p)hを測定するための方法
|
BR112015007731B1
(pt)
|
2011-10-10 |
2022-05-31 |
H. Lundbeck A/S |
Composto, composição farmacêutica que o compreende e uso do mesmo
|
JP6046154B2
(ja)
*
|
2011-10-20 |
2016-12-14 |
オリソン ヘノミクス エセ. アー. |
Lsd1阻害剤としての(ヘテロ)アリールシクロプロピルアミン化合物
|
US9487512B2
(en)
|
2011-10-20 |
2016-11-08 |
Oryzon Genomics S.A. |
(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
|
CL2014000988A1
(es)
|
2011-10-20 |
2014-11-03 |
Oryzon Genomics Sa |
Compuestos derivados de (aril o heteroaril) ciclopropilamida, inhibidores de lsd1; procedimiento para prepararlos; composicion farmaceutica que los comprende; y metodo para tratar o prevenir cancer, una enfermedad neurologica, una infeccion viral y la reactivacion viral despues de la latencia.
|
ITMI20111971A1
(it)
|
2011-10-28 |
2013-04-29 |
Mesogenics Srl |
Inibitori dell'enzima lsd-1 per l'induzione del differenziamento osteogenico
|
EP2785183B1
(en)
|
2011-11-14 |
2018-12-19 |
Merck Sharp & Dohme Corp. |
Triazolopyridinone pde10 inhibitors
|
US20140288145A1
(en)
|
2011-12-05 |
2014-09-25 |
Brandeis University |
Treatment of amyloidosis by compounds that regulate retromer stabilization
|
CN104159901B
(zh)
|
2012-03-07 |
2016-10-26 |
默克专利股份公司 |
三唑并吡嗪衍生物
|
CN102587054B
(zh)
|
2012-03-13 |
2014-05-07 |
机械科学研究总院先进制造技术研究中心 |
缸盖自动锁紧装置及包括该装置的筒子纱染色机
|
CN102579381B
(zh)
|
2012-03-30 |
2013-07-10 |
河南中帅医药科技发展有限公司 |
盐酸胍法辛缓释制剂及其制备方法
|
GB201205669D0
(en)
|
2012-03-30 |
2012-05-16 |
Agency Science Tech & Res |
Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
|
CN103373996A
(zh)
|
2012-04-20 |
2013-10-30 |
山东亨利医药科技有限责任公司 |
作为crth2受体拮抗剂的二并环衍生物
|
EP2867226B1
(en)
|
2012-06-28 |
2018-11-14 |
Novartis AG |
Complement pathway modulators and uses thereof
|
CN102772444A
(zh)
|
2012-07-06 |
2012-11-14 |
周明千 |
中药超微破壁口服片剂饮片的加工方法
|
GB201212513D0
(en)
|
2012-07-13 |
2012-08-29 |
Ucb Pharma Sa |
Therapeutic agents
|
WO2014051698A1
(en)
|
2012-09-28 |
2014-04-03 |
Vanderbilt University |
Fused heterocyclic compounds as selective bmp inhibitors
|
AU2013326867B2
(en)
|
2012-10-05 |
2018-03-08 |
Rigel Pharmaceuticals, Inc. |
GDF-8 inhibitors
|
CN105051005B
(zh)
*
|
2012-10-12 |
2017-06-13 |
武田药品工业株式会社 |
环丙胺化合物及其用途
|
CA2890897A1
(en)
|
2012-11-14 |
2014-05-22 |
The Board Of Regents Of The University Of Texas System |
Inhibition of hif-2.alpha. heterodimerization with hif 1.beta. (arnt)
|
WO2014084298A1
(ja)
|
2012-11-28 |
2014-06-05 |
京都府公立大学法人 |
リシン構造を有するlsd1選択的阻害薬
|
US9144555B2
(en)
|
2012-11-30 |
2015-09-29 |
Darlene E. McCord |
Hydroxytyrosol and oleuropein compositions for induction of DNA damage, cell death and LSD1 inhibition
|
EP2740474A1
(en)
|
2012-12-05 |
2014-06-11 |
Instituto Europeo di Oncologia S.r.l. |
Cyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
|
CA2889165A1
(en)
|
2012-12-19 |
2014-06-26 |
Wockhardt Limited |
A stable aqueous composition comprising human insulin or an analogue or derivative thereof
|
CN103054869A
(zh)
|
2013-01-18 |
2013-04-24 |
郑州大学 |
含三唑基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用
|
CN103933036B
(zh)
|
2013-01-23 |
2017-10-13 |
中国人民解放军军事医学科学院毒物药物研究所 |
2‑芳基咪唑并[1,2‑α]吡啶‑3‑乙酰胺衍生物在制备防治PTSD的药物中的用途
|
US20150376198A1
(en)
|
2013-02-18 |
2015-12-31 |
The Scripps Research Institute |
Modulators of vasopressin receptors with therapeutic potential
|
US8558008B2
(en)
|
2013-02-28 |
2013-10-15 |
Dermira, Inc. |
Crystalline glycopyrrolate tosylate
|
WO2014164867A1
(en)
|
2013-03-11 |
2014-10-09 |
Imago Biosciences |
Kdm1a inhibitors for the treatment of disease
|
CN105283552A
(zh)
|
2013-03-13 |
2016-01-27 |
澳大利亚核科学和技术组织 |
具有非功能性tspo基因的转基因非人类生物体
|
US20140343118A1
(en)
|
2013-03-14 |
2014-11-20 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
JP2016517434A
(ja)
|
2013-03-14 |
2016-06-16 |
エピザイム,インコーポレイティド |
癌を処置するための併用療法
|
US9918983B2
(en)
|
2013-05-30 |
2018-03-20 |
The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas |
Suicidal LSD1 inhibitors targeting SOX2-expressing cancer cells
|
AU2014281398B2
(en)
|
2013-06-19 |
2018-10-04 |
University Of Utah Research Foundation |
Substituted (E)-N'-(1-phenylethylidene) benzohydrazide analogs as histone demethylase inhibitors
|
UA117929C2
(uk)
|
2013-06-21 |
2018-10-25 |
Міокардіа, Інк. |
Сполуки піримідиндіону, спрямовані проти станів серцево-судинної системи
|
US9186391B2
(en)
|
2013-08-29 |
2015-11-17 |
Musc Foundation For Research Development |
Cyclic peptide inhibitors of lysine-specific demethylase 1
|
US9556170B2
(en)
|
2013-08-30 |
2017-01-31 |
University Of Utah Research Foundation |
Substituted-1H-benzo[d]imidazole series compounds as lysine-specific demethylase 1 (LSD1) inhibitors
|
US9770514B2
(en)
|
2013-09-03 |
2017-09-26 |
ExxPharma Therapeutics LLC |
Tamper-resistant pharmaceutical dosage forms
|
US20160220494A1
(en)
|
2013-09-13 |
2016-08-04 |
Bayer Pharma Aktiengesellschaft |
Pharmaceutical compositions containing refametinib
|
KR101568724B1
(ko)
|
2013-11-13 |
2015-11-12 |
서울대학교산학협력단 |
신규한 화합물, 이의 생산 방법, 및 히스톤 디메틸라제 저해제로서 이의 용도
|
EP4257591A3
(en)
|
2013-12-11 |
2023-11-22 |
Celgene Quanticel Research, Inc. |
Inhibitors of lysine specific demethylase-1
|
US9670210B2
(en)
|
2014-02-13 |
2017-06-06 |
Incyte Corporation |
Cyclopropylamines as LSD1 inhibitors
|
US9428470B2
(en)
|
2014-02-13 |
2016-08-30 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
WO2015123408A1
(en)
|
2014-02-13 |
2015-08-20 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
US9346776B2
(en)
|
2014-02-13 |
2016-05-24 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic compound
|
WO2015123437A1
(en)
|
2014-02-13 |
2015-08-20 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
CR20200362A
(es)
|
2014-02-13 |
2020-10-26 |
Incyte Corp |
CICLOPROPILAMINA COMO INHIBIDORES DE LA LSD1 (Divisional 2016-0395)
|
CN103893163B
(zh)
|
2014-03-28 |
2016-02-03 |
中国药科大学 |
2-([1,1′-联苯]-4-基)2-氧代乙基4-((3-氯-4-甲基苯基)氨基)-4-氧代丁酸酯在制备lsd1抑制剂药物中的应用
|
KR102379518B1
(ko)
|
2014-04-02 |
2022-03-25 |
브리스톨-마이어스 스큅 컴퍼니 |
비아릴 키나제 억제제
|
AU2015244698B2
(en)
|
2014-04-11 |
2019-05-16 |
Takeda Pharmaceutical Company Limited |
Cyclopropanamine compound and use thereof
|
EP2929884A1
(en)
|
2014-04-11 |
2015-10-14 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Pharmaceutical combinations of dabigatran and h2-receptor antagonists
|
US10130618B2
(en)
|
2014-04-11 |
2018-11-20 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Pharmaceutical combinations of dabigatran and proton pump inhibitors
|
CN103961340B
(zh)
|
2014-04-30 |
2019-06-25 |
南通中国科学院海洋研究所海洋科学与技术研究发展中心 |
一类lsd1抑制剂及其应用
|
CA2953005C
(en)
|
2014-05-30 |
2023-03-14 |
Ieo - Istituto Europeo Di Oncologia S.R.L. |
Cyclopropylamine compounds as histone demethylase inhibitors
|
CN104119280B
(zh)
|
2014-06-27 |
2016-03-16 |
郑州大学 |
含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用
|
WO2016007722A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as lsd1 inhibitors
|
TWI687419B
(zh)
|
2014-07-10 |
2020-03-11 |
美商英塞特公司 |
作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪
|
US9758523B2
(en)
|
2014-07-10 |
2017-09-12 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as LSD1 inhibitors
|
US9695180B2
(en)
|
2014-07-10 |
2017-07-04 |
Incyte Corporation |
Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
|
GB201417828D0
(en)
|
2014-10-08 |
2014-11-19 |
Cereno Scient Ab |
New methods and compositions
|
CN104173313B
(zh)
|
2014-08-25 |
2017-05-17 |
杭州朱养心药业有限公司 |
利伐沙班片剂药物组合物
|
JP6653116B2
(ja)
|
2014-08-27 |
2020-02-26 |
日本ケミファ株式会社 |
オルメサルタンのプロドラッグ製剤
|
CN106852142B
(zh)
|
2014-10-08 |
2020-08-21 |
豪夫迈·罗氏有限公司 |
作为醛固酮合酶抑制剂的螺二胺衍生物
|
CN107660205B
(zh)
|
2015-04-03 |
2021-08-27 |
因赛特公司 |
作为lsd1抑制剂的杂环化合物
|
SG11201708097SA
(en)
|
2015-04-03 |
2017-10-30 |
Bristol Myers Squibb Co |
Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
|
WO2016156597A1
(en)
|
2015-04-03 |
2016-10-06 |
Mutabilis |
Heterocyclic compounds and their use in preventing or treating bacterial infections
|
EP3334709A1
(en)
|
2015-08-12 |
2018-06-20 |
Incyte Corporation |
Salts of an lsd1 inhibitor
|
CN105232488B
(zh)
|
2015-10-15 |
2021-05-04 |
上海凌凯医药科技有限公司 |
一种含有利伐沙班的固体药物组合物
|
SG11201805645QA
(en)
|
2015-12-29 |
2018-07-30 |
Mirati Therapeutics Inc |
Lsd1 inhibitors
|
WO2017130933A1
(ja)
|
2016-01-25 |
2017-08-03 |
国立大学法人熊本大学 |
神経変性疾患治療剤
|
PE20190377A1
(es)
|
2016-04-22 |
2019-03-08 |
Incyte Corp |
Formulaciones de un inhibidor de lsd 1
|
BR112019014759A2
(pt)
|
2017-01-18 |
2020-03-03 |
Vanderbilt University |
Compostos heterocíclicos fundidos como inibidores seletivos de bmp
|
UA125592C2
(uk)
|
2017-03-16 |
2022-04-27 |
Джянгсу Хенгруй Медісін Ко., Лтд. |
ПОХІДНА ГЕТЕРОАРИЛ[4,3-c]ПІРИМІДИН-5-АМІНУ, СПОСІБ ЇЇ ОТРИМАННЯ ТА ЇЇ МЕДИЧНІ ЗАСТОСУВАННЯ
|
GEP20237560B
(en)
|
2018-07-05 |
2023-10-25 |
Incyte Corp |
Fused pyrazine derivatives as a2a / a2b inhibitors
|
US10968200B2
(en)
|
2018-08-31 |
2021-04-06 |
Incyte Corporation |
Salts of an LSD1 inhibitor and processes for preparing the same
|